Business
Cell MedX Corp. provides additional information on its observational clinical trial with diabetes and related conditions
Cell MedX Corp. provides additional information on its observational clinical trial with diabetes and related conditions.
About this update from Stimcell Energetics Inc.
[{"type":"text","content":"Cell MedX Corp. (OTCQB:CMXC, 9CX:MUN), (“Cell MedX” or the “Company”), is an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. As reported in a news releases issued by the Company on January 24, 2018, an observational clinical trial was completed by Dr. Richard Tytus and his team at Hamilton Medical Research Group in Hamilton, Ontario (the “Trial”) and submitted to Health Canada for final approval by Nutrasource Diagnostics Inc. Since then, the Company has examined the results of the Trial more thoroughly and wishes to provide more information on the significance of the findings.DiabetesType 1 diabetes is an auto-immune disorder which causes the pancreas to produce little or no insulin and leads to high blood glucose levels. Type 2 diabetes occurs as a result of decreased insulin effectiveness or production which also leads to high blood glucose levels. During the Trial, the effectiveness of the Company’s eBalance therapy as an adjunct treatment for diabetes and related complications in Type 1 and Type 2 diabetics was assessed over 3 months.In non-diabetics, insulin rises sharply after a meal, attaches to a receptor on the surface of muscle tissue, allows glucose to rapidly enter and then dissipates. In Type 2 diabetic, insulin is less able to stimulate the entry of glucose into muscle tissue, leading to high blood glucose levels and sustained elevated levels of insulin.When hemoglobin (“Hb”) in the red blood cells combines with glucose, it is referred to as “glycated hemoglobin” or “HbA1c”. The amount of glucose that combines with Hb is directly proportional to the total amount of sugar that is in the blood at that time. Measuring HbA1c can provide an estimate of average glucose levels over the 8 to 12 week life span of red blood cells.After 3 months of eBalance treatments, average fasting blood glucose levels declined by 12.3% from 10.5 to 9.2 millimoles per litre. Plasma insulin declined by 46.7% from 168 to 78 picomoles per litre. These results indicate that, on average, the blood glucose uptake was increased and that less insulin was required to achieve that uptake. HbA1c levels declined by 0.16% from 8.36% to 8.20%. A longer double-blind, placebo controlled study may be conducted in the future to d...